Skip NavigationSkip to Content
Return Return to Search Results

Proliferative Lesions of Oviduct and Uterus in Cd-1 Mice Exposed Prenatally to Tamoxifen

  1. Author:
    Diwan, B. A.
    Anderson, L. M.
    Ward, J. M.

  2. Author Address

    Diwan BA NCI INTRAMURAL RES SUPPORT PROGRAM SAIC FREDERICK FREDERICK CANC RES & DEV CTR BLDG 538 FREDERICK, MD 21702 USA NCI COMPARAT CARCINOGENESIS LAB FREDERICK CANC RES & DEV CTR FREDERICK, MD 21702 USA NCI VET & TUMOR PATHOL SECT OFF LAB ANIM SCI FREDERICK CANC RES & DEV CTR FREDERICK, MD 21702 USA
    1. Year: 1997
  2. Journal: Carcinogenesis
    1. 18
    2. 10
    3. Pages: 2009-2014
  4. Type of Article: Article
  1. Abstract:

    Tamoxifen (TAM) is widely used as adjuvant breast cancer therapy after surgery and as a chemopreventive agent in women of child-bearing age, However, TAM therapy has been shown to result in an increased incidence of endometrial carcinoma in women. The present study was designed to investigate the effects of TAM (5 mg/kg and 7.5 mg/kg body wt) given i.g. to pregnant CD-1 mice (1x/day, days 12 through 18 of gestation) on their female offspring, Progressive proliferative hyperplasia of the oviduct was frequently seen in TAM-exposed offspring, reaching 100% incidence by 52 weeks in both treatment groups. These females also developed progressive proliferative uterine lesions, including moderate/severe cystic endometrial hyperplasia (34-50%) and polypoid adenomas (27-30%) between 53 and 78 weeks, Deciduomas (15%) occurred at young ages (12 and 24 weeks) while leiomyomas (14%), a malignant leiomyosarcoma, and ovarian granulosa cell tumors (14%), were found between 72 and 78 weeks, Our findings thus suggest a strong association between transplacental TAM and reproductive tract abnormalities in female CD-1 mice. [References: 24]

    See More

  1. Keywords:

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel